Drugs / KSVCBD
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07613411 | Jun 2026 → Dec 2028 expected | autoimmune disease | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07620314 | Jul 2026 → Dec 2028 expected | non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07620275 | Jun 2026 → Dec 2028 expected | plasma cell myeloma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSVCBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07620314 ↗ |
| Known as | KSVCBD injection | “KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA.” NCT07620275 ↗ |
| Action | Deplete | “Simultaneously targeting BCMA to eliminate plasma cells producing anti-lentivirus and anti-CD19 scFv antibodies enables repeated infusion.” NCT07620275 ↗ |
| Modality | Cell therapy | “KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product.” NCT07613411 ↗ |
| Route | Intravenous | “KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA and is administered by IV infusion.” NCT07613411 ↗ |
| Target | CD19 | “KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA and is administered by IV infusion.” NCT07613411 ↗ |